Literature DB >> 6602174

The "lazy" NK cells of Chediak-Higashi syndrome.

S R Targan, R Oseas.   

Abstract

Natural killer (NK) function, measured in a short-term (4-hr) 51Cr-release assay, is profoundly depressed in circulating PBL of donors with Chediak-Higashi syndrome (CHS). In this study, we demonstrate that CHS NK cells can express relatively normal lytic function after prolonged exposure in vitro to high levels of activating as well as cytotoxic stimuli. After activation with the human cloned interferon (B1) for 24 hr, CHS NK cells have lytic activity comparable to unactivated normals in a 4-hr 51Cr-release assay. In addition, after 5 days of activation with mitomycin C-treated B cell lines, CHS NK cells have levels of activity similar to those of activated normals but are defective in generating cytotoxic cells capable of lysing the stimulator B cell. Even though CHS NK cells are defective in a 4-hr 51Cr-release assay, after 16 hr they enhance their killing capability 200 to 400-fold. In fact, after 16 hr of interaction with K562 target cells, CHS NK cells are capable of releasing NK soluble cytotoxic factors. These results are consistent with the hypothesis that CHS NK cells have all the necessary cellular structures and molecules required for them to function as lytic effector cells, but their lack of cytotoxic function is due to a relative refractoriness in initiating the post-binding lytic mechanism.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602174

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Cytolytic mechanisms involved in non-MHC-restricted cytotoxicity in Chediak-Higashi syndrome.

Authors:  T Nakazawa; K Agematsu; K Yasui; T Onodera; R Inoue; H Kaneko; N Kondo; M Yamamoto; N Kayagaki; H Yagita; K Okumura; A Komiyama
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

2.  Defective postbinding lysis underlies the impaired natural killer activity in factor VIII-treated, human T lymphotropic virus type III seropositive hemophiliacs.

Authors:  M Katzman; M M Lederman
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

3.  Chronic active Epstein-Barr virus infection in patients with Chediak-Higashi syndrome.

Authors:  F Merino; W Henle; P Ramírez-Duque
Journal:  J Clin Immunol       Date:  1986-07       Impact factor: 8.317

4.  Genetic and physical mapping of the Chediak-Higashi syndrome on chromosome 1q42-43.

Authors:  F J Barrat; L Auloge; E Pastural; R D Lagelouse; E Vilmer; A J Cant; J Weissenbach; D Le Paslier; A Fischer; G de Saint Basile
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

5.  Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation.

Authors:  F J Barrat; F Le Deist; M Benkerrou; P Bousso; J Feldmann; A Fischer; G de Saint Basile
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 6.  Formation and function of the lytic NK-cell immunological synapse.

Authors:  Jordan S Orange
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

7.  Skin fibroblasts from individuals with Chediak-Higashi Syndrome (CHS) exhibit hyposensitive immunogenic response.

Authors:  Le Wang; Kamila Rosamilia Kantovitz; Andrew Robert Cullinane; Francisco Humberto Nociti; Brian Lee Foster; Joseph Concepcion Roney; Anne Bich Tran; Wendy Jewell Introne; Martha Joan Somerman
Journal:  Orphanet J Rare Dis       Date:  2014-12-21       Impact factor: 4.123

8.  Differences in Granule Morphology yet Equally Impaired Exocytosis among Cytotoxic T Cells and NK Cells from Chediak-Higashi Syndrome Patients.

Authors:  Samuel C C Chiang; Stephanie M Wood; Bianca Tesi; Himmet Haluk Akar; Waleed Al-Herz; Sandra Ammann; Fatma Burcu Belen; Umran Caliskan; Zühre Kaya; Kai Lehmberg; Turkan Patiroglu; Huseyin Tokgoz; Ayşegül Ünüvar; Wendy J Introne; Jan-Inge Henter; Magnus Nordenskjöld; Hans-Gustaf Ljunggren; Marie Meeths; Stephan Ehl; Konrad Krzewski; Yenan T Bryceson
Journal:  Front Immunol       Date:  2017-04-18       Impact factor: 7.561

Review 9.  Human immunodeficiency syndromes affecting human natural killer cell cytolytic activity.

Authors:  Hyoungjun Ham; Daniel D Billadeau
Journal:  Front Immunol       Date:  2014-01-21       Impact factor: 7.561

Review 10.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.